SCHEDULE 13G/A: Perceptive Advisors Discloses 8.1% Beneficial Ownership in Amicus Therapeutics
Beneficial Ownership Report
Perceptive Advisors LLC and its affiliates have reported an 8.1% beneficial ownership stake in Amicus Therapeutics, Inc., holding 24,245,952 shares as of December 31, 2024.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G Amendment No. 3 regarding their beneficial ownership in Amicus Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 24,245,952 shares of Amicus Therapeutics, Inc. Common Stock.
- This ownership represents 8.1% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 298,805,773 outstanding shares, as reported in Amicus Therapeutics' Quarterly Report on Form 10-Q filed on November 6, 2024.
- Perceptive Advisors LLC serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd., which directly holds the shares.
- Joseph Edelman is the managing member of Perceptive Advisors LLC and is deemed to beneficially own the shares through his control of Perceptive Advisors LLC.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine regulatory disclosure of beneficial ownership and does not contain operational or financial performance updates that would typically influence sentiment.
Positives
- The disclosure of a significant stake by a specialized life sciences investment firm like Perceptive Advisors may signal institutional confidence in Amicus Therapeutics' long-term prospects.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Amicus Therapeutics' future performance or strategic outlook.
Industry Context
Perceptive Advisors is a prominent investment firm focused on the life sciences sector. Their significant stake in Amicus Therapeutics, a biotechnology company, aligns with their investment strategy and specialization in the pharmaceutical and biotech industries.
Stakeholder Impact
- Shareholders may view the continued significant stake by a specialized institutional investor as a positive indicator of confidence in the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 11/06/2024 | Date Amicus Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting 298,805,773 outstanding shares of Common Stock. |
| 12/31/2024 | Date of event which requires the filing of this Schedule 13G statement, reflecting the beneficial ownership. |
| 02/14/2025 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
Keywords
Amicus Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, beneficial ownership, common stock, biotechnology, pharmaceuticals, institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.